Authors: SCHILSKY RL HOHNEKER J RATAIN MJ JANISCH L SMETZER L LUCAS VS KHOR SP DIASIO R VONHOFF DD BURRIS HA

Citation: Rl. Schilsky et al., PHASE-I CLINICAL AND PHARMACOLOGICAL STUDY OF ENILURACIL PLUS FLUOROURACIL IN PATIENTS WITH ADVANCED CANCER, Journal of clinical oncology, 16(4), 1998, pp. 1450-1457

Authors: WYNGAARDEN J POTTS J COTTER F MARTIN RR MEHTA V ECKSTEIN F LEVIN A WEISS B BLACK L COLE R CROOKE S KREIG A DIASIO R

Citation: J. Wyngaarden et al., ANTISENSE-97 - A ROUND-TABLE ON THE STATE OF THE INDUSTRY, Nature biotechnology, 15(6), 1997, pp. 519-524

Authors: TAKIMOTO C LU Z ZHANG R DIASIO R LIANG M LARSON L CANTILENA L GREM J ALLEGRA C CHU E

Citation: C. Takimoto et al., REVERSIBLE 5-FLUOROURACIL-ASSOCIATED ENCEPHALOPATHY IN A DIHYDROPYRIMIDINE DEHYDROGENASE (DPD) DEFICIENT PATIENT, Clinical pharmacology and therapeutics, 59(2), 1996, pp. 9-9

Authors: SPARANO JA WADLER S SCHWARTZ EL DIASIO R

Citation: Ja. Sparano et al., CLINICAL AND PHARMACOLOGICAL STUDIES OF INTERFERON AND CHEMOTHERAPY IN GASTROINTESTINAL AND BREAST-CANCER, International journal of clinical pharmacology research, 13(1), 1993, pp. 1-9